| Literature DB >> 30024758 |
Jitendra Wankar1, Francesca Bonvicini2, Gabor Benkovics3, Valentina Marassi4,5, Milo Malanga3, Eva Fenyvesi3, Giovanna Angela Gentilomi2,6, Pierluigi Reschiglian4,5, Barbara Roda4,5, Ilse Manet1.
Abstract
Clofazimine (CLZ) is an antibiotic with a promising behavior against Gram-positive bacteria; however, the drug is completely insoluble in water and accumulates in fat tissues. We explored nanocarriers, labeled and not labeled with rhodamine, consisting of negatively charged sulfobutylether-β-cyclodextrins for CLZ loading. A new oligomeric carrier was obtained cross-linking βCyD with epichlorohydrin followed by sulfonation in a strongly alkaline aqueous medium. The oligomeric carrier has a MW of 53 kDa and forms small nanoparticles of a few tens of nm. With aqueous solutions containing a 25 mg/mL oligomeric carrier, we loaded up to 0.5 mg/mL of drug. The oligomers exhibited a 10-fold better loading capacity compared to monomers and formed nanoparticles with a size in the 20-60 nm range after drug loading. Circular dichroism confirmed encapsulation of the CLZ in the nanocarriers. All carriers with or without CLZ are not cytotoxic up to 1 μM, while CLZ alone is highly cytotoxic at the same concentration. The drug has IC50 values below 100 nM against S. epidermidis. The same holds true also for clinical isolates of S. epidermidis, some displaying MDR. So, the selectivity index significantly increased for CLZ/carrier systems compared to the drug alone. Taken all together, our results open new avenues for the clinical application of this antibiotic.Entities:
Keywords: clofazimine; cyclodextrin; drug delivery; fluorescence lifetime imaging; nanoparticles; staphylococci
Mesh:
Substances:
Year: 2018 PMID: 30024758 DOI: 10.1021/acs.molpharmaceut.8b00321
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939